Shopping Cart
- Remove All
Your shopping cart is currently empty
Inebilizumab
Catalog No. T76713Cas No. 1299440-37-1
Alias VIB-0551, MT-0551, MEDI 551, 16C4-aFuc
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.
Inebilizumab
Inebilizumab
Catalog No. T76713Alias VIB-0551, MT-0551, MEDI 551, 16C4-aFucCas No. 1299440-37-1
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $157 | In Stock | |
| 5 mg | $397 | In Stock | |
| 10 mg | $659 | In Stock | |
| 25 mg | $987 | In Stock | |
| 50 mg | $1,360 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Inebilizumab"
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
- $157
Size
QTY
Daratumumab
T9918945721-28-8
Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.
- $147
Size
QTY
Lonigutamab
VB-421, VB421, hz208F2-4
T77071
Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the study of thyroid eye disease.
- $197
Size
QTY
Naratuximab
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
T817031622327-39-2
Naratuximab emtansine [1] is a humanized monoclonal antibody (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) that specifically targets CD37 (TSPAN26) and serves as the basis for creating an antibody-drug conjugate (ADC) compound.
- $239
Size
QTY
lorvotuzumab
T77406339306-30-8
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
- $368
Size
QTY
Belantamab
GSK2857914
T771292061894-48-0
Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).
- $263
Size
QTY
Glembatumumab
T774391020264-78-1
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
- $263
Size
QTY
Enfortumab
T774051448664-46-7
Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
- $289
Size
QTY
Polatuzumab
T774772279068-37-8
Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.Polatuzumab can be used to synthesize the antibody-compound coupling, Polatuzumab Vedotin.
- $195
Size
QTY
Disitamab
T771592185868-98-6
Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].
- $289
Size
QTY
Datopotamab
T9901A-0072267989-53-5
Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).
- $255
Size
QTY
Sacituzumab
Sacituzumab (anti-Trop-2), Sacituzumab
T353971796566-95-4
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.
- $163
Size
QTY
Select Batch
Concentration:3.19 mg/mL
Purity:96.2% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis. |
| In vitro | Derived from the mouse anti-human mAb HB12b, Inebilizumab had already shown impressive activity in depleting B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1]. Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1]. Inebilizumab demonstrates equal or better activity than Rituximab in depleting human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1]. |
| In vivo | In vivo, Inebilizumab (MEDI-551) (i.v.; once; 0-10 mg/kg) depletes B cells from blood and spleen by mouse macrophages, and it induces phagocytosis of murine B cells ex vivo[2]. |
| Alias | VIB-0551, MT-0551, MEDI 551, 16C4-aFuc |
| Molecular Weight | 146.60 kDa |
| Cas No. | 1299440-37-1 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Inebilizumab | purchase Inebilizumab | Inebilizumab cost | order Inebilizumab | Inebilizumab in vivo | Inebilizumab in vitro | Inebilizumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.